Browsing by Author "García, Lorena"

Now showing 1 - 13 of 13
  • Thumbnail Image
    Item
    Ácido úrico: una molécula con acciones paradójicas en la insuficiencia cardiaca
    (2011) Alcaíno, Hernán; Greig, Douglas; Castro Gálvez, Pablo Federico; Verdejo Pinochet, Hugo; Mellado Suazo, Rosemarie; García, Lorena; Díaz Araya, Guillermo; Quiroga Lagos, Clara Rosa; Chiong, Mario; Lavandero, Sergio
  • Thumbnail Image
    Item
    Angiotensin II-Regulated Autophagy Is Required for Vascular Smooth Muscle Cell Hypertrophy
    (2019) Mondaca-Ruff, David; Riquelme, Jaime A.; Quiroga Lagos, Clara Rosa; Norambuena-Soto, Ignacio; Sanhueza-Olivares, Fernanda; Villar-Fincheira, Paulina; Hernández-Díaz,Tomás; Cancino-Arenas, Nicole; San Martín, Alejandra; García, Lorena; Lavandero, Sergio; Chiong, Mario
  • Thumbnail Image
    Item
    Circulating Vascular Cell Adhesion Molecule-1 (sVCAM-1) Is Associated With Left Atrial Remodeling in Long-Distance Runners
    (FRONTIERS MEDIA SA, 2021) Contreras Briceño, Felipe; Herrera, Sebastián; Vega Adauy, Julián; Salinas, Manuel; Ocaranza Jeraldino, María Paz; Jalil Milad, Jorge; Mandiola Ovalle, Jorge; García, Lorena; Chiong, Mario; Castro Galvez, Pablo Federico; Lavandero, Sergio; Gabrielli Nervi, Luigi Arnaldo
    Introduction: An increased risk of atrial fibrillation (AF) has been demonstrated in high-performance athletes. Soluble vascular adhesion molecule-1 (sVCAM-1), a biomarker involved in inflammation and cardiac remodeling, is associated with the development of AF in the general population. However, the relationship between sVCAM-1 and left atrial (LA) remodeling has been poorly investigated in long-distance runners (LDR).Aim: To determine the association between LA remodeling and sVCAM-1 levels in LDR during the training period before a marathon race.Methods: Thirty-six healthy male LDR (37.0 +/- 5.3 years; 174.0 +/- 7.0 height; BMI: 23.8 +/- 2.8; V degrees O-2-peak: 56.5 +/- 7.3 mL center dot kg(-1)center dot min(-1)) were evaluated in this single-blind and cross-sectional study. The LDR were separated into two groups according to previous training levels: high-training (HT) (n = 18) >= 100 km center dot week(-1) and low-training (LT) (n = 18) >= 70 and <100 km center dot week(-1). Also, 18 healthy non-active subjects were included as a control group (CTR). In all participants, transthoracic echocardiography was performed. sVCAM-1 blood levels were measured baseline and immediately finished the marathon race in LDR.Results: HT showed increased basal levels of sVCAM-1 (651 +/- 350 vs. 440 +/- 98 ng center dot mL(-1) CTR, p = 0.002; and vs. 533 +/- 133 ng center dot mL(-1) LT; p = 0.003) and a post-marathon increase (Delta sVCAM-1) (651 +/- 350 to 905 +/- 373 ng center dot mL(-1); p = 0.002), that did not occur in LT (533 +/- 133 to 651 +/- 138 ng center dot mL(-1); p = 0.117). In LDR was a moderate correlation between LA volume and sVCAM-1 level (rho = 0.510; p = 0.001).Conclusions: In male long-distance runners, sVCAM-1 levels are directly associated with LA remodeling. Also, the training level is associated with basal sVCAM-1 levels and changes after an intense and prolonged exercise (42.2 km). Whether sVCAM-1 levels predict the risk of AF in runners remains to be established.
  • Thumbnail Image
    Item
    Counter-regulatory renin–angiotensin system in cardiovascular disease
    (2019) Ocaranza, María Paz; Riquelme, Jaime A.; García, Lorena; Jalil Milad, Jorge; Chiong, Mario; Santos, Robson A. S.; Lavandero, Sergio
  • No Thumbnail Available
    Item
    EPAC expression and function in cardiac fibroblasts and myofibroblasts
    (2013) Olmedo, Ivonne; Muñoz, Claudia; Guzmán, Nancy; Catalán, Mabel; Vivar, Raúl; Ayala, Pedro; Humeres, Claudio; Aránguiz, Pablo; García, Lorena; Velarde, Victoria; Díaz Araya, Guillermo
  • Thumbnail Image
    Item
    Frequency of diminished ovarian reserve in women with multiple sclerosis in Chile: An exploratory study
    (2023) Pelayo Carolina; Ciampi Díaz, Ethel Leslie; Soler León, Bernardita María; Uribe San Martín, Reinaldo Moises; Reyes Delgado, Ana Cecilia; García, Lorena; Del Canto, Adolfo; Gutiérrez Carquin, Leticia; Barrerra Hormazabal, Antonia; Jurgensen Heinrich, Lukas; Guzman Cárcamo, Ignacio; Carvajal, Andrés; Troncoso, Carlos; Carvajal, Rodrigo; Cárcamo Rodríguez, Claudia Andrea
    Introduction: Multiple Sclerosis (MS) is a chronic disease affecting around 2.8 million people worldwide. Two-thirds are women, and the mean age at diagnosis is about 30 years old. Social trends are moving towards older age at first pregnancy, both in women with and without MS. Objectives: To determine the frequency of diminished ovarian reserve (DOR) through anti-Mullerian Hormone (AMH) measurement in women with MS at fertile age and Healthy Females (HF) in Chile. Methods: Case-control, multicentric, cross-sectional study including relapsing-remitting people with MS (pwMS) between 18 and 40 years and sex and age-matched HF. We obtained a blood sample to determine AMH levels. We defined DOR as AMH <1.5 ng/mL and very-low AMH levels as <0.5 ng/mL. Also, we performed questions regarding reproductive decision-making. Results: We included 79 sex and age-matched HF and 92 pwMS, median age 32(19–40) years, median disease duration 6 (1–17)years, median EDSS 1.0 (0–6), 95% were receiving disease-modifying therapy (DMT), 70% high-efficacy DMT and 37% with a treatment that contraindicates pregnancy. DOR was observed in 24% (n = 22) of the pwMS, compared to 14% (n = 11) of the HF (p = 0.09), while very-low AMH levels were observed in 7.6% (n = 7) of pwMS and none of the HF (p = 0.0166). We observed an inverse correlation between age and AMH levels. Age was the only significant risk factor for low AMH levels in pwMS (OR 1.14 95%CI(1.00–1–31), p = 0.04), including smoking, body mass index (BMI), hormonal contraception, autoimmune comorbidity, high/low-moderate efficacy DMT, and active disease as covariables. We did not find statistically significant differences in age at diagnosis, BMI, disease duration, EDSS, autoimmune comorbidity, use of hormonal contraception, or percentage of active disease between MS women with normal vs DOR. Over 70% of pwMS desired to become pregnant in the future, while 60% considered that the diagnosis of MS was a limitation for pregnancy planning. Conclusions: No differences in DOR, measured by levels of AMH, were observed between pwMS MS and HF in Chile. As expected, AMH levels were correlated only with ageing. This information may be evaluated early during the disease course to help patients and neurologists with fertility counselling and family planning considerations regarding DMT use.
  • Thumbnail Image
    Item
    Increased active phase atrial contraction is related to marathon runner performance
    (2018) Gabrielli, Luigi; Herrera, Sebastián; Contreras Briceño, Felipe; Vega, Julián; Ocaranza, María Paz; Yáñez Díaz, Fernando; Fernández, Rodrigo; Saavedra Madariaga, Rodrigo Alejandro; Sitges, Marta; García, Lorena; Chiong, Mario; Lavandero, Sergio; Castro Gálvez, Pablo Federico
  • Thumbnail Image
    Item
    Pleiotropic effects of atorvastatin in heart failure : role in oxidative stress, inflammation, endothelial function, and exercise capacity
    (2008) Castro Gálvez, Pablo Federico; Miranda, Rodrigo; Verdejo Pinochet, Hugo; Greig, Douglas; Gabrielli, Luigi; Alcaíno, Hernán; Chiong, Mario; Bustos, Carlos; García, Lorena; Mellado Suazo, Rosemarie; Vukasovic, José Luis; Godoy J., Iván; Lavandero, Sergio
  • Thumbnail Image
    Item
    Regulation of cardiomyocyte autophagy by calcium
    (2016) Shaikh, Soni; Troncoso, Rodrigo; Criollo, Alfredo; Bravo Sagua, Roberto; García, Lorena; Morselli, Eugenia; Cifuentes, Mariana; Quest, Andrew F. G.; Hill, Joseph A.; Lavandero, Sergio
  • No Thumbnail Available
    Item
    Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
    (2022) Ciampi, Ethel; Uribe-San-Martin, Reinaldo; Soler, Bernardita; García, Lorena; Guzmán, Jorge; Pelayo, Carolina; Jürgensen, Lukas; Guzmán, Ignacio; Vera, Francisco; Galleguillos, Lorna; Cárcamo, Claudia
    Background: Safety and effectiveness outcomes in Multiple Sclerosis (MS) patients receiving different disease- modifying therapies (DMT) and different types of vaccines against SARS-CoV-2 are limited. Growing evidence coming mainly from Israel, Europe and North America using mRNA and adenoviral vector vaccines has been published. Objectives: To assess the safety and humoral response of inactivated virus and mRNA vaccines against SARS-CoV- 2 in patients with MS. Methods: Ongoing, multicentric, prospective, observational study performed between February and September 2021. Humoral response (antibodies against spike-1 protein) was determined at least 4 weeks after the complete schedule of anti-SARS-CoV-2 vaccines. Categorical outcome (positive/negative) and total antibody titres were recorded. Adverse events supposedly attributable to vaccination (AESAV) were collected. Results: 178 patients, 68% women, mean age 39.7 ±11.2 years, 123 received inactivated (Coronavac-Sinovac), 51 mRNA (Pfizer-BioNtech), and 4 adenoviral vector vaccines (CanSino n =2, Jonhson&Johnson-Jannsen n =1, Oxford-AstraZeneca n =1). Six patients had a history of COVID-19 before vaccination. Overall humoral response was observed in 66.9% (62.6% inactivated vs. 78.4% mRNA, p =0.04). Positive anti-S1-antibodies were observed in 100% of patients with no DMT (n =3), 100% with interferon/glatiramer-acetate (n =11), 100% with teriflunomide/dimethyl-fumarate (n =16), 100% with natalizumab (n =10), 100% with alemtuzumab (n =8), 90% with cladribine (n =10), and 88% with fingolimod (n =17), while 43% of patients receiving antiCD20 (n =99) were positive (38% inactivated vaccine vs. 59% mRNA vaccine, p =0.05). In the multivariate analysis including antiCD20 patients, the predictors for a positive humoral response were receiving the mRNA vaccine (OR 8.11 (1.79–36.8), p =0.007) and a lower number of total infusions (OR 0.44 (0.27–0.74) p =0.002. The most frequent AESAV was local pain (14%), with 4 (2.2%) patients experiencing mild-moderate relapses within 8 weeks of first vaccination compared to 11 relapses (6.2%) within the 8 weeks before vaccination (Chi-squared 3.41, p =0.06). Discussion: A higher humoral response rate was observed using the mRNA compared to the inactivated vaccine, while patients using antiCD20 had a significantly lower response rate, and patients using antiCD20 and fingolimod had lower antibody titres. In this MS patient cohort, inactivated and mRNA vaccines against SARS-CoV-2 appear to be safe, with no increase in relapse rate. This information may help guidelines including booster shots and types of vaccines in selected populations.
  • Thumbnail Image
    Item
    Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure
    (2008) Alcaíno, Hernán; Greig, Douglas; Chiong, Mario; Verdejo Pinochet, Hugo; Miranda, Rodrigo; Concepcion, Roberto; Vukasovic, José Luis; Díaz-Araya, Guillermo; Mellado Suazo, Rosemarie; García, Lorena; Salas, Daniela; González, Leticia; Godoy J., Iván; Castro Gálvez, Pablo Federico; Lavandero, Sergio
  • Thumbnail Image
    Item
    Sodium intake is associated with endothelial damage biomarkers and metabolic dysregulation
    (2018) Campino Johnson, María del Carmen; Baudrand Biggs, René; Valdivia, Carolina A.; Carvajal Maldonado, Cristián Andrés; Vecchiola Cárdenas, Andrea Paola; Tapia Castillo, Alejandra; Martínez Aguayo, Alejandro Gregorio; García Bruce, Hernán; García, Lorena; Allende, Fidel
  • Thumbnail Image
    Item
    Systemic vascular cell adhesion molecule-1 predicts the occurrence of post-operative atrial fibrillation
    (2011) Verdejo Pinochet, Hugo; Roldan, Juan; García, Lorena; Del Campo, Andrea; Becerra, Elia; Chiong, Mario; Mellado Suazo, Rosemarie; García, Amalia; Zalaquett Sepúlveda, Ricardo; Braun Jones, Sandra; Garayar Pulgar, Bernardita; González Bombardiere, Sergio; Lavandero, Sergio; Corbalán Herreros, Ramón